Form 4: Cocrystal Pharma Director Boosts Stake

Cocrystal Pharma Director Fred Hassan acquired 359,713 common shares and 719,426 warrants, increasing his beneficial ownership in the company.

Summary

• Fred Hassan, a Director and 10% Owner of Cocrystal Pharma, Inc. (COCP), acquired additional securities on October 28, 2025.
• Mr. Hassan purchased 359,713 units at a price of $1.39 per unit.
• Each unit consisted of one share of common stock and a warrant to purchase two shares of common stock.
• This transaction resulted in the acquisition of 359,713 shares of common stock and 719,426 warrants.
• The acquired warrants have an exercise price of $1.24 and are exercisable upon issuance, with an expiration date of January 28, 2028.
• Following this transaction, Mr. Hassan's beneficial ownership includes 1,383,009 shares of common stock (which includes shares issuable upon vesting of restricted stock units) and 719,426 warrants.
• The transaction was approved by a Special Committee of the Board of Directors, consisting of two non-employee directors, making it exempt from Section 16(b) of the Securities Exchange Act of 1934 under Rule 16b-3.

Sentiment

Score: 8

Explanation: Insider buying, especially by a significant shareholder and director, is generally viewed as a strong positive signal, indicating management's confidence in the company's future performance and valuation.

Positives

• A Director and 10% owner, Fred Hassan, significantly increased his stake in Cocrystal Pharma, Inc. by acquiring 359,713 common shares and 719,426 warrants.
• The acquisition of shares and warrants by an insider can signal strong confidence in the company's future prospects and valuation.
• The transaction was approved by a Special Committee of the Board, consisting of non-employee directors, indicating proper governance oversight for related-party transactions.

Future Outlook

NA

Industry Context

NA

Corporate Governance

Related Party Transactions

• Fred Hassan, a Director and 10% owner of Cocrystal Pharma, Inc., purchased securities directly from the issuer.
• The transaction involved the acquisition of 359,713 shares of common stock and 719,426 warrants from the company.

Stakeholder Impact

• Shareholders: Increased insider ownership may boost investor confidence, signaling management's belief in the company's value and future prospects.
• Company: The purchase of units by the director provides capital to the company.

Key Dates

Recommendation

The significant purchase of common stock and warrants by a Director and 10% owner, Fred Hassan, signals strong insider confidence in Cocrystal Pharma's future prospects. Such insider buying is often interpreted by seasoned investors as a positive indicator, suggesting that the stock may be undervalued or that positive developments are anticipated. This action, combined with the structured approval process, supports a 'buy' recommendation for investors looking for companies with strong insider conviction.

Keywords

Cocrystal Pharma, COCP, Fred Hassan, insider buying, Form 4, beneficial ownership, stock acquisition, warrants, director, 10% owner, pharmaceutical, biotech